AzTrials
AzTrials

Suicide IdeationNCT07453758

Nurse and Peer Led Suicide Prevention in Tajikistan

A study testing Suicide prevention treatment and Care as usual in people with Suicide Ideation, run by University of Illinois Chicago at 1 site in Tajikistan.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The study takes place in Tajikistan, a postwar country in Central Asia, where Dr. Weine, Dr. Pirova, Dr. Bahromov, and other collaborators successfully implemented a D43 research capacity building project and an R21 and R01 on stepped care for women's mental health in primary care. Read more about this study

Who is it for?
Ages 18 to 59 years, women only
Conditions the study is for
Suicide Ideation
What is being tested?
Suicide prevention treatment and Care as usual
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
1 siteTajikistan
Study dates
1 Jan 2026to 1 Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 59 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Tajik women age 18 to 59 who meet operationally defined criteria for moderate or high risk suicide risk. We will identify women at-risk for suicide defined as:
  • a recent suicide attempt (past 3 months)
  • recent suicidal ideation that is accompanied by either a plan or intention as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS). If they score a level 2 or higher on the C-SSRS, they are eligible. Level 2 refers to non-specific active suicidal thoughts. At level 2, a person has general, active thoughts of wanting to end their life but has not formulated a specific plan, method, or intention to act on them.
  • Other inclusion criteria are: 1) willing to participate in the SUSTAIN intervention and research procedures; and 2) able to give written informed consent.

Who cannot join

  • If they score less than a level 2 on the C-SSRS they are not eligible

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tajikistan1 site
  • PRISMA research center

    Dushanbe

About this study

The study takes place in Tajikistan, a postwar country in Central Asia, where Dr. Weine, Dr. Pirova, Dr. Bahromov, and other collaborators successfully implemented a D43 research capacity building project and an R21 and R01 on stepped care for women's mental health in primary care. This study also builds on the team's prior research that demonstrated the effectiveness of nurse- and peer-led interventions, identified risk and protective factors for suicide among women, and on the PREVAIL peer-led suicide prevention model. The specific aims for this new project are: Aim 1: Adapt the evidence-based PREVAIL model into a new SUSTAIN nurse- and peer-led suicide prevention model in primary care for women at moderate or high suicide risk in rural and urban Tajikistan using a participatory co-design process (the Transcreation Framework) with multi-level partners. Aim 2: Evaluate a pilot implementation of the SUSTAIN model in primary care among 96 women with moderate to high suicide risk, 48 randomized to SUSTAIN and 48 to an enhanced usual care condition, with both groups followed for 9 months for suicidal ideations or behaviors, mental health outcomes, and mediators. Aim 3: Assess the acceptability, feasibility, appropriateness, potential for scalability and sustainability, programmatic costs, and partnership of SUSTAIN to inform a future hybrid type 2 effectiveness-implementation pragmatic trial.

Being tested
Suicide prevention treatment, Care as usual

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Suicide prevention treatmentBehavioural

    SUSTAIN intervention is a nurse and peer-led individual, group and family sessions suicide prevention intervention. There are 9 sessions that are attended by the women (6 individual and 3 group) and 1 session that is attended by their family members; this will occur over the course of 8-12 weeks depending on timing and scheduling.

  • Care as usualBehavioural

    Enhanced usual care (EUC) control condition):

    In the 6 clinics assigned to the control condition, the women who screen positive for moderate to high suicide risk will receive enhanced usual care. They will be evaluated by a family medicine doctor who will confirm their level of risk and decide on appropriate actions. This could include an admission to inpatient psychiatry, a referral to outpatient psychiatry, or management in the family medicine clinic which may include counseling, psychiatric medication, a family meeting, or a home visit. At the very least, the family medicine doctor will provide them with a list of local crisis support resources.

Study groups in NCT07453758
Study groupRoleWhat they receive
SUSTAIN interventionExperimentalWomen in the 6 intervention clinics will be enrolled in the SUSTAIN intervention. This includes nurse and peer co-lead individual, group and family sessions. There are 9 sessions that are attended by the women (6 individual and 3 group) and 1 session that is attended by their family members; this will occur over the course of 8-12 weeks depending on timing and scheduling. The SUSTAIN Model consists of: * Six individual sessions for women at-risk of suicide (once a week for 1-1.5 hours) * Three group sessions for women at-risk of suicide (once a week for 2 hours) * One education group session for families of women at-risk of suicide (note, the women do not attend this session)
Receives: Behavioral: Suicide prevention treatment
Enhanced Care as UsualOtherIn the 6 clinics assigned to the control condition, the women who screen positive for moderate to high suicide risk will receive enhanced usual care. They will be evaluated by a family medicine doctor who will confirm their level of risk and decide on appropriate actions. This could include an admission to inpatient psychiatry, a referral to outpatient psychiatry, or management in the family medicine clinic which may include counseling, psychiatric medication, a family meeting, or a home visit. At the very least, the family medicine doctor will provide them with a list of local crisis support resources.
Receives: Behavioral: Care as usual

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Columbia Suicide Severity Rating Scale

    Suicide attempts (measured by the Columbia Suicide Severity Rating Scale) Any suicide attempt as measured according to an electronic self-report version of the Columbia Suicide Severity Rating Scale (CSSR-S). The definition of suicide attempt for the primary outcome will consist of any actual suicide attempt, aborted suicide attempt, or interrupted suicide attempt according to the CSSR-S.

    Measured: Baseline and 3, 6, 9 months post intervention

Secondary outcomes (12)
  1. Medically serious suicide attempts

    Medical record data on suicide attempts will be collected when a participant reports receiving care at an Emergency Room or hospital for reasons related on mental health or substance abuse on the Heath Services Inventory (HIS) at the 3, 6, and 9 month outcome assessments, or when a participant reports seeking medical attention for suicidal behavior during the Columbia Suicide Severity Rating Scale at the 3, 6, and 9 month outcome assessments. Whenever a participant reports received medical attention on these measures, study staff will ask the participant to provide the name of the treating facility. Before the follow-up visit is completed, the participant will be asked to sign a Request for Outside Records, allowing study staff to request medical records from any facility outside of study performance sites. Signing this form is voluntary. If a participant chooses not to sign a form, the participant's self-report will be used to measure medically serious suicide attempts.

    Measured: 3, 6, and 9 months post intervention

  2. Suicide Cognitions Scale-Short Form (SCS-S)

    A tool designed to measure intense feelings of hopelessness, unlovability, and inability to cope, often associated with chronic suicide risk.

    B-SCS employs Likert-scaling (1-5) and scores are calculated by summing the keyed responses and yields a score between 6 and 30

    Measured: 3, 6, and 9 month post intervention

  3. Beck Hopelessness Scale (BHS)

    The Beck Hopelessness Scale (BHS) is a 20-item, true/false self-report inventory designed to measure an individual's negative expectations and pessimism about the future, with higher scores indicating greater hopelessness. It assesses feelings about the future, loss of motivation, and future expectations, with total scores ranging from 0-20.

    Measured: 3, 6, 9 months post intervention

  4. Brief Reasons for Living (BRFL)

    The BRFL is a 12-item self-report measure intended to assess adaptive beliefs and expectations for living. The inventory has six subscales: fear of suicide, responsibility to family, survival and coping beliefs, child-related concerns, moral objections, and fear of social disapproval. The 12 items are scored on a 6-point scale ranging from (1) "not at all important" to (6) "extremely important". Higher scores on the BRFL scale and on its subscales reflect more reasons for living.

    Measured: 3, 6, 9 month post intervention

  5. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a 9-question, self-report tool used to screen, diagnose, and monitor depression severity by measuring symptom frequency over the past two weeks. It uses a 4-point Likert scale (0-3), with total scores ranging from 0 to 27. Higher scores indicate greater severity (5-9: Mild, 10-14: Moderate, 15-19: Moderately severe, 20-27: Severe).

    Measured: 3, 6, 9 month post intervention

  6. Generalized Anxiety Disorder-7 (GAD-7)

    The Generalized Anxiety Disorder-7 (GAD-7) is a validated, 7-item self-report questionnaire designed to screen for and measure the severity of generalized anxiety disorder in the past two weeks. Items are scored 0-3, totaling 0-21, with higher scores indicating greater anxiety severity. Scores greater than 10 typically indicate a likely anxiety disorder

    Measured: 3, 6, 9 months post intervention

  7. PTSD CheckList - Civilian Version (PCL-C)

    The PCL-C is a 17-item self-report scale based on DSM-IV criteria for PTSD, designed to assess symptom severity over the past month in civilians without linking symptoms to a specific event. It uses a 5-point Likert scale (1-5) for each item, with total scores ranging from 17 to 85. Scores above 44 indicate possible PTSD.

    Measured: 3, 6, 9 months post intervention

  8. Abuse Assessment Screen

    Abuse Assessment Screen (A.A.S.) is as a clinician-administered sexual and physical violence assessment tool for use in medical practice. A.A.S. includes five questions about the experience of abusive behavior.

    Measured: 3, 6, 9 month post intervention

  9. Pearlin Mastery Scale

    The Pearlin Mastery Scale is a 7-item survey assessing an individual's sense of control over life circumstances, measuring a key psychological coping resource. It uses a 4-point Likert scale (1=Strongly Disagree to 4=Strongly Agree), with total scores ranging from 7 to 28; higher scores indicate greater mastery.

    Measured: 3, 6, 9 months post intervention

  10. Mental Health Knowledge Schedule (MAKS)

    MAKS has been developed to measure mental health-related knowledge. The tool assesses and tracks stigma-related mental health knowledge among the general public. The Mental Health Knowledge Schedule (MAKS) uses a 5-point Likert scale to measure stigma-related knowledge (items 1-6) and illness recognition (items 7-12). Only the first 6 items are scored for knowledge, ranging from 6 to 30, with higher scores indicating greater knowledge. "Don't know" is generally scored as neutral (3).

    Measured: 3, 6, 9 months post intervention

  11. Short Form Health Survey (SF-12)

    The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.

    The SF-12 health survey is scored by transforming responses into two main components: the Physical Component Summary (PCS) and Mental Component Summary (MCS). Using norm-based scoring, the average score for each component is 50, with a standard deviation of 10. Higher scores indicate better health-related quality of life, while scores below 50 suggest lower, below-average health.

    Measured: 3, 6, 9 months post intervention

  12. Interpersonal Needs Questionnaire (INQ)

    The INQ measures beliefs about the extent to which individuals believe their need to belong is met or unmet, as well as the extent to which they perceive themselves to be a burden on the people in their lives. It uses a 7-point Likert scale (1 = "not at all true for me" to 7 = "very true for me") to rate items, with higher total scores indicating higher risk.

    Measured: 3, 6, 9 months post intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Mar 2026
  2. Study start1 Jan 2026
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07453758
Sponsor's protocol ID
2025-0021
Other IDs
R34MH136247
Status last verified
Oct 2026
First submitted
27 Feb 2026
Last updated
6 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Suicide prevention treatment and Care as usual in people with Suicide Ideation, run by University of Illinois Chicago at 1 site in Tajikistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tajikistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Columbia Suicide Severity Rating Scale (time frame: Baseline and 3, 6, 9 months post intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in